Metsera
About Metsera
Metsera is a clinical-stage biotechnology company focused on engineering and developing NuSH (nutrient-stimulated hormone) therapies for obesity and related diseases. The company pursues injectable and oral, ultra-long-acting therapies designed to be scalable and tolerable, with a strong emphasis on peptide engineering, translational science, and large-scale manufacturing. Metsera aims to deliver convenient and affordable obesity treatments and is operating within the biotech and pharmaceutical landscape; the site notes that Metsera was acquired by Pfizer, positioning the venture within Pfizer's portfolio. The content centers on obesity therapeutics and metabolic health, with global implications for weight management and related conditions.
Recent News
Biotech in 2025: A Retrospective
Pfizer’s Early Metsera Data Leaves Analysts Wanting More
Pfizer Shares Edge Higher on Strong Oncology Data Amid Flat 2026 Revenue Guidance
The 5 Largest IPOs in Biopharma History
Pfizer Searches for Novel Tumor-Selective Antigens With $865M+ Cartography Pact
Pfizer, Innovent Ink Up-to-$10.5B+ Cancer Treatment Collaboration
JPM26: Deal Hungry Novo Moves With ‘Intention’ To Put Metsera in the Rearview
The Top 10 PharmTech Videos of 2025
Pfizer Inks up to $10.5 Billion Deal with China’s Innovent Biologics
Pfizer’s Metsera-Originated Monthly GLP-1 Cuts Weight by 10.5% at Six Months
Amneal Sets $3.1B 2026 Revenue Target, Leverages GLP‑1 Manufacturing Partnership
Novartis' Vas Narasimhan Heads to Anthropic's Board; Metsera Alum Joins Structure as COO
FDA Approves the First PROTAC in History, a $1B siRNA Wave Hits Cardiometabolic Disease, and Cytokinetics Cracks Non-Obstructive HCM – This Week in Biotech #99
Biotech Investors Bet on a 2026 Rebound as Deal Activity Accelerates
10 Obesity Drug Companies to Watch in 2026
Amneal Projects $3.1B 2026 Revenue, Leverages Pfizer GLP‑1 Manufacturing Deal
Lilly Acquiring Kelonia In Largest Funded Biotech Startup Purchase In Years
Cardiometabolic Intervention: Evaluation of PCSK9 Inhibitors as the Successor to the GLP-1 Phenomenon
Pfizer Tops Wall Street Estimates, Reaffirms Outlook as Newer Products Show Growth
Obesity Biotech Verdiva Plans Big Year of Data, Explores Deals
Can Amylin Weight-Loss Drugs Compete in a World of GLP-1s?
Recent Deals
No recent deals for this company.